Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TRACON Pharmaceuticals, Inc.

Home Clinical Trial Sponsors and OrganizationsTRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc.

ACTIVE

4350 La Jolla Village Dr Ste 800, 加利福尼亚州圣迭戈县, California, United Stateswww.traconpharma.comPublic17 employeesEstablished: 2006-01-01

Also known as:

tcon

tracon pharmaceuticals

tcon.ca

td conservative etf portfolio unit

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

10

10 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2006

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

10

100.0%

Trial Status Distribution

Active, not recruiting

10

100.0%

Clinical Trials

Trials sponsored by this organization (10)

A trial in people with advanced angiosarcoma to compare the effects of treatment with an investigational medicine, TRC105, and pazopanib against the effects of pazopanib used by itself.

Active, not recruiting

Apr 2018200 participants

A trial in people with advanced angisarcoma to compare the effects of treatment with an investigational medicine, TRC105, and pazopanib against the effects of pazopanib used by itself.

Active, not recruiting

Jan 2018200 participants

A trial in people with advanced angisarcoma to compare the effects of treatment with an investigational medicine, TRC105, and pazopanib against the effects of pazopanib used by itself.

Active, not recruiting

Nov 2017200 participants

A trial in people with advanced angisarcoma to compare the effects of treatment with an investigational medicine, TRC105, and pazopanib against the effects of pazopanib used by itself.

Active, not recruiting

Oct 2017340 participants

A trial in people with advanced angisarcoma to compare the effects of treatment with an investigational medicine, TRC105, and pazopanib against the effects of pazopanib used by itself.

Active, not recruiting

Jul 2017340 participants

A trial in people with advanced angisarcoma to compare the effects of treatment with an investigational medicine, TRC105, and pazopanib against the effects of pazopanib used by itself.

Active, not recruiting

May 2017128 participants

Phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma

Active, not recruiting

Jun 2016150 participants

PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Active, not recruiting

May 2016150 participants

Page 1 of 2

Approvals

No approval data available

News

Kronos Bio Halts Istisociclib Development, Considers Strategic Alternatives

• Kronos Bio discontinued istisociclib (KB-0742) development after safety concerns arose in a Phase I/II trial for platinum-resistant high-grade serous ovarian cancer. • The trial revealed neurological adverse events in five of seven patients, leading to treatment discontinuation or dosage reduction in some participants. • Facing financial pressures, Kronos Bio is exploring strategic alternatives, including acquisition or merger, to maximize stockholder value and preserve cash. • The company is also seeking partnerships for preclinical assets KB-9558 and KB-7898, while focusing on IND application for multiple myeloma and autoimmune disorders.

On this page

Overview
Clinical Trials10
Approvals
News1

Back to Organizations